ReviewJournal of clinical medicine2019
The Clinicopathological Spectrum of Acromegaly.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- The effect of endoscopic transsphenoidal somatotroph tumors resection on pituitary hormones: systematic review and meta-analysis.World journal of surgical oncology · 2023Pooled it
- Comparative effectiveness of endoscopic and microscopic adenoma removal in acromegaly.Frontiers in endocrinology · 2023Trial
- Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.Pituitary · 2022Trial
- Growth hormone-releasing hormone, growth hormone, and neuroendocrine tumors.Journal of clinical & translational endocrinology · 2026Review
- Postoperative Pituitary MRI Findings in Acromegaly: A Pictorial Review.Diagnostics (Basel, Switzerland) · 2026Review
- Ex Vivo drug sensitivity in patient-derived 3D cultures in acromegaly and its association with clinical predictors.Pituitary · 2026Article
- Preoperative Metabolic Predictors of Granulation Subtypes in Somatotroph Tumors: A Multicenter Retrospective Cohort Study.CNS neuroscience & therapeutics · 2026Article
- Mixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients.Acta neuropathologica communications · 2026Article
- Oral mucosal health in acromegaly: clinical insights and metabolic associations.BMC oral health · 2025Article
- Silent growth hormone pituitary adenomas: a single-center study.Pituitary · 2025Article
- Management of acromegaly beyond primary surgery: efficacy and safety of repeat surgery and radiotherapy.Acta neurochirurgica · 2025Article
- PIT-1/SF-1-positive pituitary tumors in patients with acromegaly: transcriptomic perspective.Acta neuropathologica communications · 2025Article
- Clinical integration and application of the 2022 WHO pituitary tumor classification.Neuro-oncology advances · 2025Article
- Oral Health and Quality of Life in Acromegaly: A Questionnaire-Based Study.Dentistry journal · 2025Article
- A single-center prospective study evaluating the relationship of tumor consistency on remission in acromegaly patients.Scientific reports · 2025Article
- Genetic and Functional Changes in Mitochondria in the Pituitary Adenoma: The Pathogenesis and Its Therapy.Antioxidants (Basel, Switzerland) · 2024Review
- High level of aneuploidy and recurrent loss of chromosome 11 as relevant features of somatotroph pituitary tumors.Journal of translational medicine · 2024Article
- Intraocular Pressure (IOP) in Patients with Acromegaly versus Healthy Controls: A Systematic Review and Meta-Analysis.Vision (Basel, Switzerland) · 2024Review
- Unusual Presentation of Craniopharyngioma Pituitary Mass in a 71-Year-Old Female: A Case Report.Case reports in endocrinology · 2024Article
- Pathologic Characteristics of Somatotroph Pituitary Tumors-An Observational Single-Center Study.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcromegaly results from a persistent excess in growth hormone with clinical features that may be subtle or severe. The most common cause of acromegaly is a pituitary tumor that causes excessive production of growth hormone (GH), and rare cases are due to an excess of the GH-releasing hormone (GHRH) or the ectopic production of GH.
objectiveDiscuss the different diseases that present with manifestations of GH excess and clinical acromegaly, emphasizing the distinct clinical and radiological characteristics of the different pathological entities.
methodsWe performed a narrative review of the published clinicopathological information about acromegaly. An English-language search for relevant studies was conducted on PubMed from inception to 1 August 2019. The reference lists of relevant studies were also reviewed.
resultsPituitary tumors that cause GH excess have several variants, including pure somatotroph tumors that can be densely or sparsely granulated, or plurihormonal tumors that include mammosomatotroph, mixed somatotroph-lactotroph tumors and mature plurihomonal Pit1-lineage tumors, acidophil stem cell tumors and poorly-differentiated Pit1-lineage tumors. Each tumor type has a distinct pathophysiology, resulting in variations in clinical manifestations, imaging and responses to therapies.
conclusionDetailed clinicopathological information will be useful in the era of precision medicine, in which physicians tailor the correct treatment modality to each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.